Zevra Therapeutics, Inc. Cash and Cash Equivalents
Zevra Therapeutics, Inc. (ZVRA) had Cash and Cash Equivalents of $145.32 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-05
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $145.32M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $95.59M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $62.41M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $54.44M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $145.32M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $95.59M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $62.41M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $54.44M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $47.71M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $37.34M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $33.78M 10-K · filed 2026-03-09 |
| 2024-09-30 | $54.04M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $39.26M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $42.85M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $43.05M 10-K · filed 2025-03-12 |
| 2023-09-30 | $43.27M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $66.20M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $40.18M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $65.47M 10-K · filed 2024-04-01 |
| 2022-09-30 | $70.06M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $76.78M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $100.24M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $112.35M 10-K · filed 2023-03-07 |
| 2021-09-30 | $131.50M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $132.29M 10-Q · filed 2021-08-13 |
| 2021-03-31 | $75.92M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $4.21M 10-K · filed 2022-03-31 |
| 2020-09-30 | $5.27M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $6.37M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $2.36M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $3.22M 10-K · filed 2021-03-12 |
| 2019-09-30 | $6.52M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $7.31M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $13.44M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $18.41M 10-K · filed 2020-02-28 |
| 2018-09-30 | $1.79M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $16.50M 10-Q · filed 2018-08-10 |
| 2018-03-31 | $8.75M 10-Q · filed 2018-05-11 |
| 2017-12-31 | $10.87M 10-K · filed 2019-03-01 |
| 2017-09-30 | $7.83M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $12.39M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $12.88M 10-Q · filed 2017-05-22 |
| 2016-12-31 | $16.76M 10-K · filed 2018-03-30 |
| 2016-09-30 | $20.85M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $27.51M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $77.33M 10-Q · filed 2017-05-22 |
| 2015-12-31 | $32.32M 10-Q · filed 2017-05-22 |
| 2015-09-30 | $59.01M 10-Q · filed 2016-11-10 |
| 2015-06-30 | $64.22M 10-Q · filed 2016-08-11 |
| 2015-03-31 | $10.27M 10-Q · filed 2016-05-13 |
| 2014-12-31 | $10.26M 10-K · filed 2017-03-10 |
| 2014-09-30 | $19.02M 10-Q · filed 2015-11-13 |
| 2014-06-30 | $22.95M 10-Q · filed 2015-08-14 |
| 2014-03-31 | $1.05M 10-Q · filed 2015-05-29 |
| 2013-12-31 | $1.97M 10-K · filed 2017-03-10 |
| 2012-12-31 | $2.54M 10-K · filed 2016-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |